Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells

被引:22
作者
Zhang, Wenguang
Zhang, Chuanyou
Narayani, Narassa
Du, Cheng
Balaji, K. C.
机构
[1] Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA
[2] Univ Nebraska, Med Ctr, Div Urol Surg, Omaha, NE 68198 USA
关键词
apoptosis-inducing factor (AIF); apoptosis; prostate cancer; cisplatin; LNCaP cells;
D O I
10.1016/j.canlet.2007.04.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PC) is considered resistant to cisplatin chemotherapy. In order to identify novel causes of resistance to cisplatin, we explored the role of Apoptosis Inducing Factor (AIF) that mediates caspase independent apoptosis in cisplatin induced cell death in PC. Similar to treatment with pancaspase inhibitor Z-VAD-fmk, cisplatin induced apoptosis in LNCaP cells was inhibited by AIT inhibitor N-acetyl-L-cysteine (NAC), treatment of LNCaP cells with NAC prevented AIF translocation to the nucleus and over-expression of recombinant AIF gene increased apoptosis. Our results suggest that AIF is associated with cisplatin induced apoptosis in PC. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 33 条
  • [1] The PARP superfamily
    Amé, JC
    Spenlehauer, C
    de Murcia, G
    [J]. BIOESSAYS, 2004, 26 (08) : 882 - 893
  • [2] Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization
    Arnoult, D
    Gaume, B
    Karbowski, M
    Sharpe, JC
    Cecconi, F
    Youle, RJ
    [J]. EMBO JOURNAL, 2003, 22 (17) : 4385 - 4399
  • [3] Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes
    Bergmann-Leitner, ES
    Abrams, SI
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (09) : 445 - 455
  • [4] Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis
    Daugas, E
    Susin, SA
    Zamzami, N
    Ferri, KF
    Irinopoulou, T
    Larochette, N
    Prévost, MC
    Leber, B
    Andrews, D
    Penninger, J
    Kroemer, G
    [J]. FASEB JOURNAL, 2000, 14 (05) : 729 - 739
  • [5] Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin
    Dempke, W
    Voigt, W
    Grothey, A
    Schmoll, HJ
    [J]. ANTI-CANCER DRUGS, 1999, 10 (06) : 545 - 549
  • [6] Cisplatin resistance and oncogene - a review
    Dempke, W
    Voigt, W
    Grothey, A
    Hill, BT
    Schmoll, HJ
    [J]. ANTI-CANCER DRUGS, 2000, 11 (04) : 225 - 236
  • [7] FERGUSON PJ, 1995, J OTOLARYNGOL, V24, P242
  • [8] Clinical perspectives on platinum resistance
    Giaccone, G
    [J]. DRUGS, 2000, 59 (Suppl 4) : 9 - 17
  • [9] ROLE OF PROTEIN-KINASES IN ANTITUMOR DRUG-RESISTANCE
    GRUNICKE, H
    HOFMANN, J
    UTZ, I
    UBERALL, F
    [J]. ANNALS OF HEMATOLOGY, 1994, 69 (01) : S1 - S6
  • [10] Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling
    Hong, SJ
    Dawson, TM
    Dawson, VL
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (05) : 259 - 264